Alexander Philipp
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Alexander Philipp has a total of 195 co-authors. Here are the top co-authors by number of shared publications:
- Florian Paul Reiter
Division of Hepatology, Department of Medicine II, University Hospital Würzburg, Würzburg, Germany
5 shared publications - Najib Ben Khaled
Department of Medicine II University Hospital, LMU Munich Munich Germany
5 shared publications - Enrico N. De Toni
Department of Medicine II, University Hospital, Ludwig-Maximilians-University of Munich, Munich, Germany
4 shared publications Julia Mayerle
Department of Medicine II, University Hospital, Ludwig-Maximilians-University of Munich, Munich, Germany
4 shared publicationsAndreas Geier
Division of Hepatology, Department of Medicine II University Hospital Wuerzburg Wuerzburg Germany
3 shared publicationsChristian M. Lange
Department of Medicine II, University Hospital, Ludwig-Maximilians-University of Munich, Munich, Germany
3 shared publications
Latest Publications
- Open Access
- 8 October 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
ALBI ‐6—A Novel Prognostic Score Combining ALBI and Interleukin‐6 in Patients With HCC Treated With Atezolizumab and Bevacizumab
Background/Aims: Despite widespread use of combination immunotherapy in advanced liver cancer, reliable biomarkers for baseline risk stratification remain lacking. The inflammatory cytokine interleukin‐6 has established prognostic relevance in this cancer. We investigated the prognostic value of interleukin‐6 and developed a combined score (ALBI‐6) integrating interleukin‐6 with albumin–bilirubin grade, a marker of liver function. Methods: In this multicentre retrospective cohort study, 216 patients with advanced hepatocellular carcinoma treated with first‐line atezolizumab plus bevacizumab were analysed. Interleukin‐6 was measured at baseline, first response, best response, and progression. The cohort was randomly divided into a training set ( n = 98) and a validation set ( n = 90). ALBI‐6 was derived using Cox regression and evaluated against several established prognostic scores. Results: Elevated baseline interleukin‐6 was consistently associated with worse overall survival and remained independently prognostic after adjustment for tumour and clinical factors (extrahepatic spread, vascular invasion, alpha‐fetoprotein, performance status, liver function class). In the validation cohort, ALBI‐6 achieved a concordance index of 0.716 and separated patients into three risk groups with significantly different survival (log‐rank p = 0.002); ALBI‐6 was significantly more discriminative than one comparator score (modified albumin–bilirubin grade, p = 0.040), with numerically higher performance than the remaining comparators. In a separate analysis of the full cohort, ALBI‐6 significantly outperformed the CRAFITY score at all assessed time points. Bootstrap validation confirmed model stability. Conclusions: ALBI‐6 integrates systemic inflammation and liver function into a simple composite index enabling meaningful risk stratification in patients with advanced hepatocellular carcinoma treated with immunotherapy. Prospective external validation is warranted.
- 8 October 2026
- Published by Wiley in Alimentary Pharmacology & Therapeutics
Open AccessALBI ‐6—A Novel Prognostic Score Combining ALBI and Interleukin‐6 in Patients With HCC Treated With Atezolizumab and Bevacizumab
Background/Aims: Despite widespread use of combination immunotherapy in advanced liver cancer, reliable biomarkers for baseline risk stratification remain lacking. The inflammatory cytokine interleukin‐6 has established prognostic relevance in this cancer. We investigated the prognostic value of interleukin‐6 and developed a combined score (ALBI‐6) integrating interleukin‐6 with albumin–bilirubin grade, a marker of liver function. Methods: In this multicentre retrospective cohort study, 216 patients with advanced hepatocellular carcinoma treated with first‐line atezolizumab plus bevacizumab were analysed. Interleukin‐6 was measured at baseline, first response, best response, and progression. The cohort was randomly divided into a training set ( n = 98) and a validation set ( n = 90). ALBI‐6 was derived using Cox regression and evaluated against several established prognostic scores. Results: Elevated baseline interleukin‐6 was consistently associated with worse overall survival and remained independently prognostic after adjustment for tumour and clinical factors (extrahepatic spread, vascular invasion, alpha‐fetoprotein, performance status, liver function class). In the validation cohort, ALBI‐6 achieved a concordance index of 0.716 and separated patients into three risk groups with significantly different survival (log‐rank p = 0.002); ALBI‐6 was significantly more discriminative than one comparator score (modified albumin–bilirubin grade, p = 0.040), with numerically higher performance than the remaining comparators. In a separate analysis of the full cohort, ALBI‐6 significantly outperformed the CRAFITY score at all assessed time points. Bootstrap validation confirmed model stability. Conclusions: ALBI‐6 integrates systemic inflammation and liver function into a simple composite index enabling meaningful risk stratification in patients with advanced hepatocellular carcinoma treated with immunotherapy. Prospective external validation is warranted.
- Open Access
- 2 October 2026
- Published by Springer Nature in PharmacoEconomics - Open
- p. 1-11
Healthcare Utilization and Direct Medical Costs of Hepatocellular Carcinoma Treatment — A German Claims Data Study of 2778 Patients
- 2 October 2026
- Published by Springer Nature in PharmacoEconomics - Open
- p. 1-11
Open AccessHealthcare Utilization and Direct Medical Costs of Hepatocellular Carcinoma Treatment — A German Claims Data Study of 2778 Patients
- Open Access
- 1 September 2025
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 17
Treatment gaps and survival outcomes of hepatocellular carcinoma: insights from a nationwide, claims-based study
Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths in Germany. National data on the management of HCC remain scarce. Objectives: This study aims to provide an up-to-date overview of clinical characteristics, treatment modalities, and survival outcomes among patients with HCC in Germany. Design: This is a real-world retrospective study using health insurance data from BARMER. Methods: Patients with an HCC diagnosis between 2016 and 2020 were identified in the BARMER database. Comorbidities, anticancer therapies, and treatment pathways of those patients were evaluated using descriptive statistics and survival analysis. Results: A total of 2778 patients with HCC were identified. Of these, 1569 (56.5%) received any anticancer therapy. Transarterial chemoembolization (TACE; 22.3%), liver resection (LR; 20.9%), and systemic therapy (18.9%) were the most frequently used approaches. Survival varied significantly, with liver transplantation (LTx) offering the best outcomes, with a 5-year survival rate of 76%, followed by LR with 40%. Treatments with curative intent, including LTx, LR, and ablation, had a median survival of 40.4 months, compared to 9.7 months for non-curative modalities. Conclusion: In Germany, a substantial proportion of HCC patients remain untreated. Therapies with curative intent, particularly transplantation, provide relevant survival benefits. Improving surveillance efforts could enhance the proportion of patients eligible for these modalities and may represent a critical step toward improved outcomes for patients with HCC.
- 1 September 2025
- Published by SAGE Publications in Therapeutic Advances in Medical Oncology
- Vol. 17
Open AccessTreatment gaps and survival outcomes of hepatocellular carcinoma: insights from a nationwide, claims-based study
Background: Hepatocellular carcinoma (HCC) is a leading cause of cancer-related deaths in Germany. National data on the management of HCC remain scarce. Objectives: This study aims to provide an up-to-date overview of clinical characteristics, treatment modalities, and survival outcomes among patients with HCC in Germany. Design: This is a real-world retrospective study using health insurance data from BARMER. Methods: Patients with an HCC diagnosis between 2016 and 2020 were identified in the BARMER database. Comorbidities, anticancer therapies, and treatment pathways of those patients were evaluated using descriptive statistics and survival analysis. Results: A total of 2778 patients with HCC were identified. Of these, 1569 (56.5%) received any anticancer therapy. Transarterial chemoembolization (TACE; 22.3%), liver resection (LR; 20.9%), and systemic therapy (18.9%) were the most frequently used approaches. Survival varied significantly, with liver transplantation (LTx) offering the best outcomes, with a 5-year survival rate of 76%, followed by LR with 40%. Treatments with curative intent, including LTx, LR, and ablation, had a median survival of 40.4 months, compared to 9.7 months for non-curative modalities. Conclusion: In Germany, a substantial proportion of HCC patients remain untreated. Therapies with curative intent, particularly transplantation, provide relevant survival benefits. Improving surveillance efforts could enhance the proportion of patients eligible for these modalities and may represent a critical step toward improved outcomes for patients with HCC.
- Open Access
- 25 July 2025
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 16 (9) , e00893
Actual and Perceived Risk of Colorectal Neoplasia in First-Degree Relatives of Patients with Colorectal Cancer
INTRODUCTION: Individuals with a family history (FH) of colorectal cancer (CRC) are at increased risk of CRC. We aimed to assess the objective role and subjective perception of risk factors of colorectal neoplasia within this high-risk group. METHODS: Questionnaire and screening colonoscopy results were obtained from individuals aged 40–54 years with a reported FH of CRC in a first-degree relative in a multicenter cross-sectional study in Germany. Descriptive statistics characterized the cohort and distribution of risk factors. Multivariable logistic regression was used to derive adjusted odds ratios (aORs) and corresponding 95% confidence intervals (CIs) to evaluate factors associated with colorectal neoplasia and with subjectively perceived increased CRC-risk. RESULTS: Among 922 participants, 220 (23.9%) were diagnosed with colorectal neoplasia, 63 (6.8%) of these being advanced lesions. Strong associations with advanced neoplasia were observed for obesity (aOR 2.44, 95% CI 1.12–5.22), smoking (aOR 1.47, 95% CI 1.14–1.88 per 10-pack-years) and physical activity <45 minutes per day (aOR 2.51, 95% CI 1.11–5.25). For smoking and physical activity, but not for obesity, similar associations were also seen with any colorectal neoplasia. No associations were seen with number and age at diagnosis of affected family members. By contrast, the latter factors, but none of the behavioral factors were strongly associated with subjectively perceived CRC-risk. DISCUSSION: Within a cohort of individuals aged 40–54 years with a FH of CRC, obesity, smoking, and lack of physical activity represented the most prominent modifiable risk factors for the development of advanced colorectal neoplasia but did not significantly impact risk perception in these high-risk participants.
- 25 July 2025
- Published by Wolters Kluwer Health in Clinical and Translational Gastroenterology
- Vol. 16 (9) , e00893
Open AccessActual and Perceived Risk of Colorectal Neoplasia in First-Degree Relatives of Patients with Colorectal Cancer
INTRODUCTION: Individuals with a family history (FH) of colorectal cancer (CRC) are at increased risk of CRC. We aimed to assess the objective role and subjective perception of risk factors of colorectal neoplasia within this high-risk group. METHODS: Questionnaire and screening colonoscopy results were obtained from individuals aged 40–54 years with a reported FH of CRC in a first-degree relative in a multicenter cross-sectional study in Germany. Descriptive statistics characterized the cohort and distribution of risk factors. Multivariable logistic regression was used to derive adjusted odds ratios (aORs) and corresponding 95% confidence intervals (CIs) to evaluate factors associated with colorectal neoplasia and with subjectively perceived increased CRC-risk. RESULTS: Among 922 participants, 220 (23.9%) were diagnosed with colorectal neoplasia, 63 (6.8%) of these being advanced lesions. Strong associations with advanced neoplasia were observed for obesity (aOR 2.44, 95% CI 1.12–5.22), smoking (aOR 1.47, 95% CI 1.14–1.88 per 10-pack-years) and physical activity <45 minutes per day (aOR 2.51, 95% CI 1.11–5.25). For smoking and physical activity, but not for obesity, similar associations were also seen with any colorectal neoplasia. No associations were seen with number and age at diagnosis of affected family members. By contrast, the latter factors, but none of the behavioral factors were strongly associated with subjectively perceived CRC-risk. DISCUSSION: Within a cohort of individuals aged 40–54 years with a FH of CRC, obesity, smoking, and lack of physical activity represented the most prominent modifiable risk factors for the development of advanced colorectal neoplasia but did not significantly impact risk perception in these high-risk participants.
- Open Access
- 5 July 2025
- Published by Elsevier in JHEP Reports
- Vol. 7 (11)
Early mortality in atezolizumab/bevacizumab for HCC is associated with impaired liver function and alterations of systemic immunity
- 5 July 2025
- Published by Elsevier in JHEP Reports
- Vol. 7 (11)
Open AccessEarly mortality in atezolizumab/bevacizumab for HCC is associated with impaired liver function and alterations of systemic immunity
- 31 May 2025
- Published by Springer Nature
- p. 277-283
Use of Immune Checkpoint Inhibitors Prior to and After Liver Transplantation
- 31 May 2025
- Published by Springer Nature
- p. 277-283
Use of Immune Checkpoint Inhibitors Prior to and After Liver Transplantation
- Open Access
- 1 May 2025
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 12, 855-864
Prognostic Significance of Elevated Platelet Count (>200 x 10^9 per L) in BCLC Stages B and C of Hepatocellular Carcinoma: A Retrospective Multicenter Analysis
Introduction: In hepatocellular carcinoma (HCC) comorbidities related to decreased liver function or to portal hypertension often limit treatment options. Traditionally, low platelet count has been considered a negative prognostic factor in HCC, especially in early stages. However, recent evidence suggests that elevated platelet count may also predict worse outcomes in advanced stages, suggesting a stage-dependent prognostic impact. Aim: This study evaluated the prognostic role of platelet counts across BCLC stages, adjusted for portal hypertension, to improve individualized patient management. Methods: In this retrospective, multicenter study, platelet count of 1112 patients with HCC in different tumor stages was analyzed. Various platelet count cutoffs (X to Y × 10^9/L) were tested to identify the optimal prognostic threshold. To isolate the effect of platelet levels from portal hypertension, spleen diameter was incorporated as an adjustment variable in multivariate analyses, with variceal status considered when available (in about two thirds of patients). Using an optimized cut-off, survival analysis was performed using univariate and multivariate Cox proportional hazards models. Bootstrapping was performed for internal validation. Results: Platelet count outside 84– 200 × 10^9/L was associated with poorer survival (HR = 0.66, 95% CI = 0.57– 0.78, p < 0.0001). Bootstrapping showed robustness of the final model. Subgroup analysis revealed worse survival in BCLC stages B and C but not stage A for elevated platelet counts (> 200 × 10^9/L) in multivariate analysis (including spleen diameter). Conclusion: Platelet counts showed a stage-dependent prognostic impact in HCC. A platelet count above a cutoff of 200/μL at diagnosis was associated with poorer prognosis. Using this cutoff may improve survival prediction in BCLC B and C patients with potential usage for risk stratification and guidance of treatment decisions. Further external validation is required to confirm these findings and evaluate their clinical applicability.
- 1 May 2025
- Published by Taylor & Francis in Journal of Hepatocellular Carcinoma
- Vol. ume 12, 855-864
Open AccessPrognostic Significance of Elevated Platelet Count (>200 x 10^9 per L) in BCLC Stages B and C of Hepatocellular Carcinoma: A Retrospective Multicenter Analysis
Introduction: In hepatocellular carcinoma (HCC) comorbidities related to decreased liver function or to portal hypertension often limit treatment options. Traditionally, low platelet count has been considered a negative prognostic factor in HCC, especially in early stages. However, recent evidence suggests that elevated platelet count may also predict worse outcomes in advanced stages, suggesting a stage-dependent prognostic impact. Aim: This study evaluated the prognostic role of platelet counts across BCLC stages, adjusted for portal hypertension, to improve individualized patient management. Methods: In this retrospective, multicenter study, platelet count of 1112 patients with HCC in different tumor stages was analyzed. Various platelet count cutoffs (X to Y × 10^9/L) were tested to identify the optimal prognostic threshold. To isolate the effect of platelet levels from portal hypertension, spleen diameter was incorporated as an adjustment variable in multivariate analyses, with variceal status considered when available (in about two thirds of patients). Using an optimized cut-off, survival analysis was performed using univariate and multivariate Cox proportional hazards models. Bootstrapping was performed for internal validation. Results: Platelet count outside 84– 200 × 10^9/L was associated with poorer survival (HR = 0.66, 95% CI = 0.57– 0.78, p < 0.0001). Bootstrapping showed robustness of the final model. Subgroup analysis revealed worse survival in BCLC stages B and C but not stage A for elevated platelet counts (> 200 × 10^9/L) in multivariate analysis (including spleen diameter). Conclusion: Platelet counts showed a stage-dependent prognostic impact in HCC. A platelet count above a cutoff of 200/μL at diagnosis was associated with poorer prognosis. Using this cutoff may improve survival prediction in BCLC B and C patients with potential usage for risk stratification and guidance of treatment decisions. Further external validation is required to confirm these findings and evaluate their clinical applicability.
- 20 July 2023
- Published by Elsevier in European Journal of Cancer
- Vol. 192, 113248
Changing treatment landscape associated with improved survival in advanced hepatocellular carcinoma: a nationwide, population-based study
- 20 July 2023
- Published by Elsevier in European Journal of Cancer
- Vol. 192, 113248
Changing treatment landscape associated with improved survival in advanced hepatocellular carcinoma: a nationwide, population-based study
- Open Access
- 27 October 2022
- Published by Elsevier in JHEP Reports
- Vol. 5 (1) , 100620
Efficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma
- 27 October 2022
- Published by Elsevier in JHEP Reports
- Vol. 5 (1) , 100620
Open AccessEfficacy and safety of immune checkpoint inhibitor rechallenge in individuals with hepatocellular carcinoma
- Open Access
Sorafenib Versus Lenvatinib-Based Sequential Systemic Therapy for Advanced Hepatocellular Carcinoma: A Real-World Analysis
The optimal treatment sequence of tyrosine kinase inhibitor (TKI)-based therapy in patients with hepatocellular carcinoma (HCC) remains unclear. Therefore, sequential systemic therapy after first-line therapy with sorafenib or lenvatinib was compared in a retrospective real-world cohort. In total, 164 patients with HCC were included. Child B cirrhosis was present in 26 patients (16.5%), whereas 132 patients (83.5%) had preserved liver function. In total, 72 patients (44%) discontinued systemic therapy after first-line therapy while 51 (31%) and 31 (19%) patients received 2 or more treatment lines. Most notably, median overall survival (mOS) was influenced by liver functional status and patient performance status at the beginning of first-line therapy. Patients receiving a sequential therapy regimen had significantly longer mOS compared to patients that discontinued systemic therapy after omitting first-line treatment. The choice of the initial TKI did not impact mOS. A clear deterioration of liver function could be observed during the course of TKI-based treatment.
Open AccessSorafenib Versus Lenvatinib-Based Sequential Systemic Therapy for Advanced Hepatocellular Carcinoma: A Real-World Analysis
The optimal treatment sequence of tyrosine kinase inhibitor (TKI)-based therapy in patients with hepatocellular carcinoma (HCC) remains unclear. Therefore, sequential systemic therapy after first-line therapy with sorafenib or lenvatinib was compared in a retrospective real-world cohort. In total, 164 patients with HCC were included. Child B cirrhosis was present in 26 patients (16.5%), whereas 132 patients (83.5%) had preserved liver function. In total, 72 patients (44%) discontinued systemic therapy after first-line therapy while 51 (31%) and 31 (19%) patients received 2 or more treatment lines. Most notably, median overall survival (mOS) was influenced by liver functional status and patient performance status at the beginning of first-line therapy. Patients receiving a sequential therapy regimen had significantly longer mOS compared to patients that discontinued systemic therapy after omitting first-line treatment. The choice of the initial TKI did not impact mOS. A clear deterioration of liver function could be observed during the course of TKI-based treatment.